Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer ; volume:29 ; number:11-12 ; day:12 ; month:10 ; year:2024 ; pages:2047-2073 ; date:12.2024
Apoptosis ; 29, Heft 11-12 (12.10.2024), 2047-2073, 12.2024

Creator: Sethy, Bidyadhar
Upadhyay, Richa
Narwanti, Iin
Yu, Zih-Yao
Lee, Sung-Bau
Liou, Jing-Ping

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10495-024-02023-7

URN: urn:nbn:de:101:1-2501272107152.670020476125

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:21 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Sethy, Bidyadhar
Upadhyay, Richa
Narwanti, Iin
Yu, Zih-Yao
Lee, Sung-Bau
Liou, Jing-Ping
SpringerLink (Online service)

Other Objects (12)

Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer

Targeting a cell state common to triple‐negative breast cancers

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention

Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer

Targeting a cell state common to triple‐negative breast cancers

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention

Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer

Targeting a cell state common to triple‐negative breast cancers

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention

Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer

Targeting a cell state common to triple‐negative breast cancers

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention

Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer

Targeting a cell state common to triple‐negative breast cancers

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention

Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer

Targeting a cell state common to triple‐negative breast cancers

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention

Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

Related objects

Reset password